Compugen Reports First Quarter 2023 Results
On track to deliver initial findings from studies with the triple blockade of PVRIG, TIGIT and PD-1 in patients with MSS CRC and platinum resistant ovarian...
Source: prnewswire.com
Page 19 - Compugen News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Compugen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Compugen Today - Breaking & Trending Today
70,800 Shares in Compugen Ltd. (NASDAQ:CGEN) Bought by Stockman Wealth Management Inc.
Stockman Wealth Management Inc. acquired a new stake in Compugen Ltd. (NASDAQ:CGEN – Get Rating) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 70,800 shares of the biotechnology company’s stock, valued at approximately $51,000. Stockman Wealth Management Inc. owned 0.08% of Compugen […]
Source: wkrb13.com
Compugen to Release First Quarter 2023 Results on Monday, May 15, 2023
HOLON, Israel, May 1, 2023 /PRNewswire/ -- Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will... | May 1, 2023
Source: marketscreener.com
Compugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Presentation at the 20th CIMT Annual Meeting
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE:CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Source: prnewswire.com
FAK Inhibitors Market Growing Rapidly, Estimates DelveInsight | Verastem, GlaxoSmithKline, Merck Sharp & Dohme, Pfizer, InxMed are Expected to Contribute to Growth
/PRNewswire/ -- DelveInsight's FAK Inhibitors Competitive Landscape report delivers an in-depth understanding of the FAK inhibitors and the FAK inhibitors...
Source: prnewswire.com